An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB).

Finally, both intepirdine groups failed to demonstrate a statistical benefit over placebo on any of the tertiary endpoints at week 24, although there was a trend toward significance favoring the 70 mg/day group on the COWAT score and the NPI Parts A+B subscore (Table 2 ).

also in 3,729 other papers